Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab for Sickle Cell Vaso-Occlusive Pain Crisis
NCT01932554Phase 2Withdrawn
- Sponsor
- Saint Louis University
- Start
- Nov 2013
- Primary completion
- Mar 2015
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Abciximab with Placebo (2 arms). Primary endpoint: Duration of hospitalization. Planned start Nov 2013; status: withdrawn.
02
Drugs
abciximab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01932554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01932554.